Patent application number | Description | Published |
20090023226 | Variant Integrin Polypeptides and Uses Thereof - Polypeptides comprising all or part of a variant integrin α subunit A domain and its flanking region are described. In solution or in membrane-associated form, the A domain polypeptides of the invention exists predominantly in a high affinity conformation. In the polypeptides of the invention, referred to as variant integrin polypeptides, a crucial isoleucine or glutamic acid residue is altered. For example, the glutamic acid can be either deleted or replaced with different amino acids residue, e.g., glutamine, aspartic acid, or alanine The variant integrin polypeptides of the invention selectively impair binding of activation-dependent ligands, but not independent ligands. They are useful in screening assays for the identification of molecules that enhance binding of variant polypeptides with impaired binding. In addition, they are useful in distinguishing between activation-dependent ligands and activation-independent ligands. They are also useful for generating antibodies, e.g., monoclonal antibodies, which bind to the impaired form of an integrin. Some such antibodies recognize an epitope that is either not present or not accessible on an integrin that is in the high affinity conformation. The variant integrin polypeptides of the invention can be derived from any integrin α subunit that could be used therapeutically. | 01-22-2009 |
20090221094 | Anthrax Polypeptide Binding - Methods are disclosed for detecting anthrax protective antigen polypeptides and inhibiting their binding to β2 integrin α. A domain polypeptides, for example β2 integrin receptors. The disclosed methods are useful, for example, in diagnosing the presence of an anthrax toxin in the environment or in a subject and also for reducing anthrax intoxication in a subject. The methods can also be used to identify compounds that inhibit binding of an anthrax toxin to a β2 integrin. | 09-03-2009 |
20100056503 | Compounds for modulating integrin CD11b/CD18 - The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency. | 03-04-2010 |
20100136681 | CELLULAR COMPOSITIONS FOR THE TREATMENT OF KIDNEY DISEASE AND USES THEREOF - As described in more detail below, the present invention provides cellular compositions for the treatment or prevention of kidney disease. The invention is based, at least in part, on the discovery of a population of cortical peritubular Flk1- and Seal-expressing kidney cells having a high tubulogenic potential. | 06-03-2010 |
20100233135 | COMPOSITIONS AND METHODS FOR HEMATOPOIETIC STEM CELL EXPANSION OR FOR MODULATING ANGIOGENESIS - The present invention provides compositions and methods featuring ZBP-89 polypeptides or nucleic acid molecules for expanding a hematopoietic stem cell population or for modulating angiogenesis. | 09-16-2010 |
20110155667 | Microfluidic Device for Blood Dialysis - The invention provides microfluidic devices and methods of using such devices for filtering solutions, such as blood. | 06-30-2011 |
20130045967 | COMPOUNDS FOR MODULATING INTEGRIN CDIIb/CDI8 - The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency. | 02-21-2013 |
20140303026 | Compounds for Modulating Integrin CD11B/CD18 - The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency. | 10-09-2014 |